Related Experiment Video
Updated: Jun 26, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Felipe Correa Geyer1, Jorge Sergio Reis-Filho
1Molecular Pathology Laboratory, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
International Journal of Surgical Pathology
|December 24, 2008
Summary
Gene expression profiling offers new insights into breast cancer biology and classification. While promising for treatment decisions, current molecular signatures primarily benefit estrogen receptor-positive breast cancer patients.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Breast cancer is a complex disease with diverse subtypes and behaviors.
- Current classification relies on histopathology, with limited additional prognostic markers.
- High-throughput molecular technologies, particularly gene expression profiling, are advancing understanding.
Purpose of the Study:
- To review the impact of gene expression profiling on understanding breast cancer.
- To discuss the clinical management implications of molecular taxonomy and signatures.
- To highlight the current limitations of predictive signatures in breast cancer.
Main Methods:
- Analysis of microarray-based gene expression data.
- Development of molecular classification systems for breast cancer.
- Generation and evaluation of prognostic/predictive gene signatures.
Main Results:
- Gene expression profiling has revealed a molecular taxonomy of breast cancer.
- Numerous prognostic and predictive signatures have been identified.
- Most identified signatures show limited predictive power for estrogen receptor-negative disease.
Conclusions:
- Gene expression profiling significantly enhances the understanding of breast cancer heterogeneity.
- Molecular signatures hold promise for improving breast cancer treatment decisions.
- Further research is needed to develop robust signatures applicable to all breast cancer subtypes.
